The need for new cancer medicines remains great, and we are committed to helping to address this need. Sanofi has a strong heritage in oncology and has laid out a strategy to re-establish itself as a leader in cancer treatment.
Now as part of Sanofi Genzyme, we are concentrating on building our oncology business in areas such as prostate cancer where we have a significant presence and currently provide important options for patients.
We also have a special focus on the promising field of immuno-oncology in which a patient’s immune system is used to fight cancer cells. We are building a pipeline of potential treatments based on this approach through partnerships with researchers and other companies.
Last Updated: 11/10/2016